What is Zolex Therapeutics' primary focus?

Zolex Therapeutics focuses on developing new classes of orally active, small-molecular-weight antibiotics to target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains.

When was Zolex Therapeutics founded?

Zolex Therapeutics was founded in August 2016.

What is the current status of Zolex Therapeutics?

Zolex Therapeutics is currently inactive, as of November 2018.

Where is Zolex Therapeutics headquartered?

Zolex Therapeutics is headquartered in Tel Aviv-Yafo, Israel.

How many employees does Zolex Therapeutics have?

Zolex Therapeutics has 1-10 employees.

What is the total amount of funding Zolex Therapeutics has raised?

Zolex Therapeutics has raised a total of $500,000.

When did Zolex Therapeutics receive its last funding round?

Zolex Therapeutics received a Grant round in December 2016 for $500,000.

Who are the leaders of Zolex Therapeutics?

Zolex Therapeutics is led by Dr. Lewis Neville and Dr. Ziv Lifshitz.

Zolex Therapeutics

Treatment for Drug-resistant Bacterial Infections

Health Tech & Life Sciences

Non Active, Nov 2018

Pre-Funding Tel Aviv-Yafo, Israel Founded 2016

Last updated 2026-06-18

Total raised

—

Last: Grant 2016-12

Stage

Pre-Funding

Founded

2016

Headcount

—

Tel Aviv-Yafo, Israel

Sector

Health Tech & Life Sciences

About

Zolex Therapeutics is a recently established drug company focusing on the development of new classes of orally active, small-molecular-weight antibiotics that target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains. Zolex Therapeutics is located within the RadBioMed Accelerator at Ramat Hachayal, Tel Aviv, and is led by Dr. Lewis Neville and Dr. Ziv Lifshitz.

Offices

Tel Aviv-Yafo, Israel · HQ / main office

Q&A

What is Zolex Therapeutics' primary focus?: Zolex Therapeutics focuses on developing new classes of orally active, small-molecular-weight antibiotics to target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains.
When was Zolex Therapeutics founded?: Zolex Therapeutics was founded in August 2016.
What is the current status of Zolex Therapeutics?: Zolex Therapeutics is currently inactive, as of November 2018.
Where is Zolex Therapeutics headquartered?: Zolex Therapeutics is headquartered in Tel Aviv-Yafo, Israel.
How many employees does Zolex Therapeutics have?: Zolex Therapeutics has 1-10 employees.
What is the total amount of funding Zolex Therapeutics has raised?: Zolex Therapeutics has raised a total of $500,000.
When did Zolex Therapeutics receive its last funding round?: Zolex Therapeutics received a Grant round in December 2016 for $500,000.
Who are the leaders of Zolex Therapeutics?: Zolex Therapeutics is led by Dr. Lewis Neville and Dr. Ziv Lifshitz.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

Identifiers & details

Founded	2016-8
Status reason	Non Active, Nov 2018

About

Offices

Q&A

Sectors & technology

Tags

Identifiers & details

Generate Slim Page

Log in